Having trouble viewing this email? View in your browser.
ESCMID Logo

11 December 2018
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

ESCMID Postgraduate Course on drug resistant Gram-negatives in Greece

Registrations are now open for the postgraduate education course ‘Phenotypic and Molecular approaches for Detection and Control of Carbapenem- and Colistin-resistant Gram-negatives’, to be held in Volos, Greece, from 23-24 May, 2019. Organised by ESGARS and ESGMD, this course will comprise state-of-the-art lectures dealing with phenotypic and molecular diagnostic approaches of multi-resistant nosocomial pathogens. Find the course programme and register on the course website here.

› Read more
OPEN CALLS | APPLICATIONS

One week left to submit your comments on the mucormycosis guideline manuscript

The manuscript of the collaborative global guideline on mucormycosis enters its last week of the public consultation phase. In order to comment, reach out to us to receive the manuscript and comments form and send in your feedback before Monday December 17th!

› Read more

EITaF News: Migrants, screening and vaccination. A guidance from ECDC

EITaF has reported a new guidance document released by the European Centre for Disease Control (ECDC), advising about screening and vaccination of recently-arrived migrants.The report suggests that is effective, and also cos-effective, to screen migrants for latent tuberculosis, HIV, hepatitis B and C, strongyloidiasis and schistosomiasis, conditional on the burden of disease in the country of origin of migrants.You can read the EITaF report, which contains a link to the ECDC document, on the EITaF Outbreak News page.

› Read more
 

Save the date for IMMEM XII - 18-21 September 2019 – Dubrovnik, Croatia

Make sure to save the date for the 12th International Meeting on Microbial Epidemiological Markers (IMMEM XII), to be held in Dubrovnik, Croatia, from 18-21 September 2019.This meeting is organized jointly by ESCMID and ESGEM, and will take on the theme: “Moving towards genome-based pathogen surveillance – lessons learnt and challenges ahead." Read more about the meeting and view the programme on the ESCMID website.

› Read more
 

CMI highlight: mumps-measles-rubella (MMR) vaccine

Belgian researchers investigated if a difference in seroneutralising capacity against the mumps-measles-rubella (MMR) vaccine and wild type viruses exists and if waning immunity could be detected. In their study, they tested 570 serum samples (age group 2-3y (N=96), 8-9y (N=95), 13-14y (N=94), 18-20y (N=96), 24-26y (N=92) and 50+ (N=97)) for their neutralizing capacity against the vaccine and wild type viruses. Neutralising antibodies against the vaccine strain were present in 81% (84/97) of the 2-3y, 70% (70/95) of the 8-9y, 76% (76/94) of the 13-14y, 73% (73/96) of the 18-20y, 62% (62/92) of the 24-26y and 75% (75/97) of the 50+ age group serum samples. For all age groups, only about half of these serum samples were also positive for the wild type virus. The geometric mean titres for the vaccine and wild type virus for all younger age groups, except 24-26y, were significantly different, demonstrating poor in vitro cross-neutralisation. The authors conclude that a possible contribution of antigenic differences between the genotype A and G mumps virus as well as other immune factors, in addition to lower-than-optimal vaccination coverage and waning immunity, could explain the poor in vitro cross-neutralisation and should be further studied.

› Read more
 

Combatting Antimicrobial Resistance in Europe

Combatting Antimicrobial Resistance in Europe (COMBACTE) is a key project of the European Commissions’ New Drugs For Bad Bugs (ND4BB) programme, which together with the Innovative Medicines Initiative (IMI) is part of the collaborative R&D efforts to tackle antimicrobial resistance. With 55 academic partners and 11 EFPIA partners, COMBACTE is a private-public partnership in which industry and academia join forces to boost the development of novel treatments.
Watch the video showcasing COMBACTE’s solid foundation for conducting high quality multiple multisite international clinical trials in the area of antimicrobial drugs development.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.